5 Key Takeaways
-
1
Biopharma's success now hinges on operational execution, not just scientific innovation, as companies face rising R&D costs and regulatory challenges.
-
2
Continuous manufacturing is becoming a strategic capability, offering higher yields and sustainability, despite the challenges of transforming legacy systems.
-
3
Half of large biopharma firms are accelerating US manufacturing investments, reframing expansions as national commitments amid geopolitical pressures.
-
4
The industry is shifting towards modular, multi-product facilities that balance specialization and adaptability to meet evolving market demands.
-
5
A talent gap in R&D and manufacturing is emerging, prompting companies to enhance in-house capabilities and prioritize workforce wellbeing and engagement.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
